Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma
Lionel Perrier,
Anne Lefranc,
David Pérol,
Philippe Quittet,
Aline Schmidt-Tanguy,
Carole Siani,
Christian Peretti,
Bertrand Favier,
Pierre Biron,
Philippe Moreau,
Jacques Bay,
Séverine Lissandre,
Fabrice Jardin,
Daniel Espinouse and
Catherine Sebban
Applied Health Economics and Health Policy, 2013, vol. 11, issue 2, 129-138
Abstract:
This study found no evidence that the use of pegfilgrastim is associated with greater cost in lymphoma and myeloma patients after high-dose chemotherapy and PBSC transplantation. Copyright Springer International Publishing Switzerland 2013
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
http://hdl.handle.net/10.1007/s40258-013-0011-7 (text/html)
Access to full text is restricted to subscribers.
Related works:
Working Paper: Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma (2013)
Working Paper: Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma (2011)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:11:y:2013:i:2:p:129-138
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258
DOI: 10.1007/s40258-013-0011-7
Access Statistics for this article
Applied Health Economics and Health Policy is currently edited by Timothy Wrightson
More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().